Measurement of 1, 5-anhydroglucitol in blood and saliva: from non-targeted metabolomics to biochemical assay. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Halama, Anna; Kulinski, Michal; Kader, Sara; Satheesh, Noothan; Abou-Samra, Abdul; Suhre, Karsten; Mohammad, Ramzi
• Is Part Of: Journal of translational medicine. Volume 14:Issue 1(2016)
• Page Start: 1
• Page End: 9
• Publication Date: 2016-12
• Subjects: Medicine, Experimental -- Periodicals; Human experimentation in medicine -- Periodicals; Therapeutics -- Periodicals; 615.50724
• DOI: 10.1186/s12967-016-0897-6
• Languages: English
• ISSNs: 1479-5876

Abstract

Abstract Background Diabetes testing using saliva, rather than blood and urine, could facilitate diabetes screening in public spaces. We previously identified 1, 5-anhydro-d -glucitol (1, 5-AG) in saliva as a diabetes biomarker. The Glycomark™ assay kit is FDA approved for 1, 5-AG measurement in blood. Here we evaluated its applicability for 1, 5-AG quantification in saliva. Methods Using pooled saliva samples, we validated Glycomark™ assay use with a RX Daytona+ clinical chemistry analyser. We then used this set-up to analyse 82 paired blood and saliva samples from a diabetes case–control study, for which broad mass spectrometry-based characterization of the blood and saliva metabolome was also available. Osmolality was measured to account for potential variability in saliva samples. Results The technical variability of the read-outs for the pooled saliva samples (CV = 2.05 %) was comparable to that obtained with manufacturer-provided blood surrogate quality controls (CV = 1.38–1.8 %). We found a high correlation between Glycomark assay and mass spectrometry measurements of serum 1, 5-AG (r2 = 0.902), showing reproducibility of the non-targeted metabolomics results. The significant correlation between the osmolality measurements performed at two independent platforms with the time interval of 2 years (r2 = 0.887), also indicates the sample integrity. The assay read-out for saliva was not correlated with the mass spectrometry-based 1, 5-AG saliva measurements. Comparison with the full saliva metabolome revealed a high correlation of the saliva assay read-outs with galactose. Conclusions Glycomark™ assay read-outs for saliva were stable and replicable. However, the signal was dominated by galactose, which is biochemically similar to 1, 5-AG and absent in blood. Adapting the 1, 5-AG kit for saliva analysis will require enzymatic depletion of galactose. This should be feasible, since the assay already includes a similar step for glucose depletion from blood samples.